Study on Using Elranatamab for Personalized Maintenance After Transplant in Multiple Myeloma Patients

Inclusion Criteria

• Have undergone a stem cell transplant as part of initial treatment for newly diagnosed IgG or IgA multiple myeloma.
• Received initial treatment with at least three drugs, including a proteasome inhibitor and an immunomodulatory drug, with or without an anti-CD38 antibody.
• Showed at least a partial response to treatment at the time of study screening after the transplant.
• Tested positive for minimal residual disease (MRD) 100 days after the transplant, indicating some remaining cancer cells.
• Have a performance status score of 2 or less, meaning fully active or able to carry out light work.
• Have resolved any side effects from previous treatments to a mild level before joining the study.
• Have adequate blood and organ function, including:
  • Platelet count of at least 75,000 per microliter.
  • Neutrophil count of at least 1,000 per microliter.
  • Hemoglobin level of at least 8 g/dL without recent transfusions.
  • Normal liver and kidney function as indicated by specific blood tests.
• Agree to use effective contraception during the study and for 5 months after treatment, if of childbearing potential.

Exclusion Criteria

• Cannot identify a specific marker for tracking the disease.
• Have had another cancer, except for certain skin or prostate cancers, unless treatment was completed over 2 years ago with no signs of disease.
• Currently taking other experimental treatments.
• Have had previous treatment targeting BCMA.
• Have cancer that has spread to the brain or spinal cord.
• Have had severe allergic reactions to similar drugs as elranatamab.
• Have uncontrolled illnesses, such as plasma cell leukemia or active infections.
• Are pregnant or breastfeeding. Women must have a negative pregnancy test before starting treatment.
• Have HIV unless on effective treatment with an undetectable viral load for at least 6 months.